Markets

Teva Pharmaceuticals presented positive real-world data on AUSTEDO XR® for tardive dyskinesia (TD) at the 2025 Psych Congress. A survey of 209 TD patients showed significant treatment satisfaction, with over 94% reporting movement improvement and over 89% expressing high overall satisfaction. Furthermore, 77% reported improved social comfort and emotional well-being, and 96% found the medication easy to take. 96% of patients expressed interest in continuing treatment.

Supreme Critical Metals (VRCFF) announced the grant of 2,675,000 stock options to management, employees, and consultants at $0.22 per share, exercisable over 3 years. The company also amended its Silver Vista option agreement, opting to issue 500,000 shares at $0.17 per share and grant a 0.6% NSR to Robert Weicker instead of investing $100,000 in the property by December 31, 2025, pending CSE approval. These moves aim to strategically position the company within the metals market.

C4 Therapeutics announced positive Phase 1 results for cemsidomide in relapsed/refractory multiple myeloma. The drug demonstrated a 50% overall response rate at the highest dose, a favorable safety profile with no treatment discontinuations, and promising immunomodulatory effects. The company plans to initiate Phase 2 trials in Q1 2026 for fourth-line therapy and Phase 1b trials in Q2 2026 for second-line therapy in combination with BCMA BiTE, pursuing two potential accelerated approval pathways. The trial included 72 heavily pre-treated patients.

H World Group is expanding further into Southeast Asia with new JI Hotels in Kuala Lumpur and Phnom Penh. This marks H World’s entry into Malaysia and strengthens JI Hotel’s presence in the region. The Kuala Lumpur property is set to open in Q4 2026, while the Phnom Penh hotels are scheduled for Q2 and Q3 2026. This expansion is driven by growing demand in Southeast Asia’s hospitality sector and is part of H World’s broader strategy to leverage its complete ecosystem for growth in Asia Pacific.

Pony.ai is entering the Singaporean market in partnership with ComfortDelGro to launch autonomous vehicle (AV) services, initially in the Punggol district. This move aligns with Singapore’s smart mobility vision and aims to address driver shortages. The partnership builds on a previous MoU and a successful pilot program in Guangzhou. The Singaporean government supports AV integration, with plans to deploy AVs within public housing estates. Pony.ai currently operates driverless Robotaxi services in multiple Chinese cities and is expanding globally, including partnerships in Qatar and Luxembourg.

BioNxt Solutions (BNXTF) completed a debt settlement with an arm’s length creditor, settling a $225,010 debt via share issuance (112,505 shares at CAD$1.00) and a $112,505 cash payment. The newly issued shares are subject to a four-month and one-day holding period according to CSE policies. This move aims to strengthen financial footing while preserving cash for core operations, though it may result in minor shareholder dilution. BioNxt focuses on bioscience innovation, particularly drug delivery technologies.

On September 19, 2025, Five Point Holdings, LLC announced the expiration of its cash tender offer for its 10.500% Senior Notes due 2028. A significant $471.5 million (over 90%) was tendered. Five Point expects to accept all validly tendered notes by September 23 and pay on September 25, funded by a new $450 million offering of 8.000% Senior Notes due 2030 and cash reserves. The move aims to streamline capital structure and reduce interest expense, allowing for future development.

National Healthcare Properties (NHP) announced quarterly dividends on its preferred stock (NHPAP/NHPBP), signaling stability in the healthcare REIT sector. A dividend of $0.4609375 per share for Series A and $0.4453125 for Series B will be paid on October 15, 2025, to shareholders of record on October 3, 2025. This reflects NHP’s commitment to consistent returns and confidence in its financial health within the evolving healthcare real estate market. NHP specializes in seniors housing and outpatient medical facilities.

Algernon Pharmaceuticals (AGNPF) shareholders approved a new Series 1 Preferred Share class with a 10% annual dividend and convertibility into common shares. Following approval, the company will issue preferred shares and warrants related to past transactions. All board nominees were elected with over 95% approval. Algernon plans to rebrand as Algernon Health Inc., expanding into Alzheimer’s Disease diagnostics and neuroimaging clinics across North America, representing a strategic shift to diversify revenue streams.

Unusual Machines (UMAC) has appointed Nathaniel Kennedy as VP of Marketing to lead multi-brand strategy amid domestic production growth. Kennedy, reporting to EVP Stacy Wright, brings 25+ years of experience in e-commerce and digital transformation. He will oversee marketing for Rotor Riot, Fat Shark, and UMAC’s broader portfolio, focusing on defense and enterprise sectors. UMAC, a provider of NDAA-compliant drone components, aims to capitalize on the expanding U.S. drone market, valued at $17.5B and projected to reach $115B by 2032.